Smarter Team

About the Author Smarter Team

Smarter Analyst was established to fill a gap in financial reporting for sell-side investors, where they can read exclusive reports in real time. Smarter Analyst provides coverage of equities research, unique analyst insights, and outstanding articles from knowledgeable contributors, in addition to the latest stock market news, all hand-picked by our editors.

H.C. Wainwright Likes Aurinia Pharmaceuticals’ Opportunity at Hand in the Lupus Nephritis Market

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has enticing clinical potential that has caught the eyes of more than one bull who have sounded off on …

Synergy Pharmaceuticals: Should You Buy the Dip Ahead of FDA Approval?

Shares of biopharma Synergy Pharmaceuticals (NASDAQ:SGYP) are now almost half the price one month ago following a controversial equity offering. With prices so …

Oppenheimer Gets Bearish on Pricey Roku Stock

Roku Inc (NASDAQ:ROKU) had just had quite the earnings party, with investors sending shares skyrocketing November 9th on back of an impressive first …

ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s Opportunity

ACADIA Pharmaceuticals (NASDAQ:ACAD) just yielded a third quarter outclass that has one of the Street’s top analysts impressed in the upshot. What commercial …

BTIG Suggests One Stock to Buy and One to Proceed with Caution

Innovative healthcare stock Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has massive upside potential according to financial services firm BTIG, as it takes rare bearish stance …

Valeant 3Q Beat Has Not Swayed Wells Fargo from Sounding the Alarm

Valeant Pharmaceuticals (NYSE:VRX) has gotten some of the Street excited after a much-needed third quarter beat to re-ignite confidence after a string of …

Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market

Dynavax Technologies (NASDAQ:DVAX) after five years of “torturous” waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of …

Omeros Story Continues to Get Better, but Reimbursement Risk Remains

The fundamentals behind Omeros’ (NASDAQ:OMER) eye drug Omidria continue to get better, but Cantor analyst Elemer Piros believes the company still needs to remove …

Canaccord’s Confident Take: Synergy Pharmaceuticals Could See Exciting Commercial Potential Boost Come 2018

Synergy Pharmaceuticals (NASDAQ:SGYP) stock may be getting some heat in the market today after releasing third quarter results yesterday, yet one bullish voice …

MannKind Has Much Room for Upside in Diabetes Market: Here’s Why

MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts